Nektar Therapeutics (NKTR)

Market Cap	1.16B
Revenue (ttm)	62.60M
Net Income (ttm)	-120.74M
Shares Out	20.34M
EPS (ttm)	-7.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	342,873
Open	57.99
Previous Close	57.69
Day's Range	55.67 - 58.10
52-Week Range	6.48 - 66.92
Beta	1.28
Analysts	Strong Buy
Price Target	106.33 (+86.87%)
Earnings Date	Nov 6, 2025

About NKTR

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution pro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 3, 1994
• Employees: 61
• Stock Exchange: NASDAQ
• Ticker Symbol: NKTR
• Website: https://www.nektar.com

Financial Performance

In 2024, Nektar Therapeutics's revenue was $98.43 million, an increase of 9.22% compared to the previous year's $90.12 million. Losses were -$118.96 million, -56.91% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for NKTR stock is "Strong Buy." The 12-month stock price target is $106.33, which is an increase of 86.87% from the latest price.

Price Target

$106.33

(86.87% upside)

Analyst Consensus: Strong Buy